@article{841fd2cd62954f988c9dce0c39ab473b,
title = "Risk of Parkinson's disease dementia related to level I MDS PD-MCI",
abstract = "Background: The International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria. Methods: We analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow-up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia. Results: Level I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia. Conclusions: Level I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria.",
keywords = "Parkinson's disease, dementia, mild cognitive impairment, neuropsychological tests, survival analysis",
author = "{on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”} and Jeroen Hoogland and Boel, {Judith A.} and {de Bie}, {Rob M.A.} and Schmand, {Ben A.} and Geskus, {Ronald B.} and Dalrymple-Alford, {John C.} and Connie Marras and Adler, {Charles H.} and Daniel Weintraub and Carmen Junque and Pedersen, {Kenn F.} and Brit Mollenhauer and Goldman, {Jennifer G.} and Tr{\"o}ster, {Alexander I.} and Burn, {David J.} and Irene Litvan and Geurtsen, {Gert J.}",
note = "Funding Information: C. Dalrymple-Alford reports grants from Brain Research New Zealand-Rangahau Roro Aotearoa, Neurological Foundation of New Zealand, Canterbury Medical Research Foundation (NZ), Health Research Council of New Zealand, and Freemasons of New Zealand. Connie Marras reports funding from the Canadian Institutes of Health Research and the Michael J. Fox Foundation. Charles H. Adler reports grants from the NINDS, Arizona Biomedical Research Commission, and Michael J. Fox Foundation. Jennifer G. Goldman reports grants from NIH and the Michael J. Fox Foundation. Alexander I. Tr{\"o}ster reports grants from the Michael J. Fox Foundation during the conduct of the study. Irene Litvan reports grants from the Michael J. Fox Foundation during the conduct of the study. Gert J. Geurtsen reports grants from the Michael J. Fox Foundation and Dutch Parkinson{\textquoteright}s Disease Foundation during the conduct of the study. Jeroen Hoogland, Judith A. Boel, Rob M.A. de Bie, Ronald B. Geskus, Ben A. Schmand, Daniel Weintraub, Carme Jun-gu{\'e}, Kenn F. Pedersen, Brit Mollenhauer, and David J. Burn report no conflicts of interest related to the research in this report. Funding Information: Funding agencies: This study was funded by the Michael J. Fox Foundation and the Dutch Parkinson{\textquoteright}s Disease Foundation. Funding Information: agencies: This study was funded by the Michael J. Fox Foundation and the Dutch Parkinson's Disease Foundation. Publisher Copyright: {\textcopyright} 2019 International Parkinson and Movement Disorder Society",
year = "2019",
month = mar,
day = "1",
doi = "https://doi.org/10.1002/mds.27617",
language = "English",
volume = "34",
pages = "430--435",
journal = "Movement disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "3",
}